Market Overview

Teva Launches Generic Version of Pfizer's Detrusitol

Related TEVA
Teva Announces UK High Court Gives Positive Judgment In The Company's Patent Case Against AstraZeneca
Notable Hedge Funds Disclose Additions And Reductions To Holdings
Sofinnova Ventures Closes $500M Fund (Fox Business)

We are pleased to announce the launch of generic Tolterodine 1mg and 2mg film-coated tablets, and Tolterodine XL (Mariosea XL) 4mg capsules.

Tolterodine is a generic version of Detrusitol ^® (tolterodine) from Pfizer.  Tolterodine XL (Mariosea XL) is a generic version of Detrusitol ^® XL (tolterodine XL) from Pfizer.  Both are indicated in the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.  Please see the Summaries of Product Characteristics for more in-depth information.

Tolterodine and Tolterodine XL (Mariosea XL) are available immediately in the award-winning Teva 360 livery.

Kim Innes, Commercial Director at Teva said: "With the launch of tolterodine in all strengths and formulations, we're making more medicines accessible for more people. We've now launched twenty-four new products in 2012, and the launch of tolterodine is our twelfth patent expiry of the year so far. It adds to Teva's portfolio of medicines, which is already the UK's widest."

"More than 1.2 million prescriptions are written each year in the UK ^[ ^1 ^] for tolterodine or tolterodine XL, and the availability of generic tolterodine will save the NHS millions of pounds each year. It and other patent expiries provide pharmacy the opportunities for increasing margins and keeping costs down, and also mean we at Teva continue to do our bit in saving the NHS over £9bn a year through the availability of generic medicines."

Posted-In: News FDA

 

Related Articles (TEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters